Retraction: Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome

Retraction: Innate Immune Sensing of Modified Vaccinia Virus Ankara (MVA) Is Mediated by TLR2-TLR6, MDA-5 and the NALP3 Inflammasome

Bibliographic Details
Main Author:	The Editors
Format:	Article
Language:	English
Published:	Public Library of Science (PLoS) 2022-01-01
Series:	PLoS Pathogens
Online Access:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789094/?tool=EBI

Similar Items

Diversity of cell death signaling pathways in macrophages upon infection with modified vaccinia virus Ankara (MVA)
by: Lioba Klaas, et al.
Published: (2021-10-01)

Recombination-mediated genetic engineering of a bacterial artificial chromosome clone of modified vaccinia virus Ankara (MVA).
by: Cottingham, M, et al.
Published: (2008)

Genome Sequencing of a Camelpox Vaccine Reveals Close Similarity to Modified <i>Vaccinia virus</i> Ankara (MVA)
by: Maurilia Marcacci, et al.
Published: (2020-07-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA)
Published: (2011-01-01)

Correction: Recombination-Mediated Genetic Engineering of a Bacterial Artificial Chromosome Clone of Modified Vaccinia virus Ankara (MVA).
by: Matthew G. Cottingham, et al.
Published: (2011-01-01)

Cardiac Safety in Clinical Trials with Preventive HIV Vaccine Candidates Based on Modified Vaccinia Ankara (MVA)
by: Schmidt, C, et al.
Published: (2008)

Safety and immunogenicity of IMVAMUNE®, a third-generation vaccine based on the modified vaccinia Ankara (MVA) strain
by: L. F. Stovba, et al.
Published: (2023-04-01)

Clinical development of Modified Vaccinia virus Ankara vaccines
by: Gilbert, S
Published: (2013)

Clinical development of Modified Vaccinia virus Ankara vaccines.
by: Gilbert, S
Published: (2013)

Evaluation of the protective potential of a recombinant modified vaccinia virus Ankara (MVA) encoding rift valley fever virus (RVFV) glycoproteins in lambs
by: Busquets, N, et al.
Published: (2011)

Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya.
by: Hanke, T, et al.
Published: (2002)

Immunogenicity and Safety of Modified Vaccinia Ankara (MVA) Vaccine—A Systematic Review and Meta-Analysis of Randomized Controlled Trials
by: Lior Nave, et al.
Published: (2023-08-01)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
by: Olga Vladimirovna Orlova, et al.
Published: (2022-09-01)

Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects.
by: Howles, S, et al.
Published: (2010)

Modified Vaccinia virus Ankara-based vaccines in the era of personalized immunotherapy of cancer
by: Kaïdre Bendjama, et al.
Published: (2017-09-01)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
by: Malachy I. Okeke, et al.
Published: (2017-10-01)

Interaction of TLR4 and TLR8 in the Innate Immune Response against Mycobacterium Tuberculosis
by: Shruthi Thada, et al.
Published: (2021-02-01)

Expression of Dectin-1 and Enhanced Activation of NALP3 Inflammasome Are Associated with Resistance to Paracoccidioidomycosis
by: Vera Lucia Garcia Calich, et al.
Published: (2015-09-01)

Studies of a prophylactic HIV-1 vaccine candidate based on modified vaccinia virus Ankara (MVA) with and without DNA priming: effects of dosage and route on safety and immunogenicity.
by: Peters, B, et al.
Published: (2007)

Ty virus-like particles, DNA vaccines and Modified Vaccinia Virus Ankara; comparisons and combinations.
by: Gilbert, S, et al.
Published: (1999)

Modified Vaccinia Virus Ankara as a Viral Vector for Vaccine Candidates against Chikungunya Virus
by: Juan García-Arriaza, et al.
Published: (2021-08-01)

The Role of the Oxidative State and Innate Immunity Mediated by TLR7 and TLR9 in Lupus Nephritis
by: Raquel Echavarria, et al.
Published: (2023-10-01)

Safety and immunogenicity of DNA/modified vaccinia virus ankara malaria vaccination in African adults.
by: Moorthy, V, et al.
Published: (2003)

Recombinant modified vaccinia virus Ankara efficiently restimulates human cytotoxic T lymphocytes in vitro.
by: Dorrell, L, et al.
Published: (2000)

Viruses utilize ubiquitination systems to escape TLR/RLR-mediated innate immunity
by: Shanzhi Huang, et al.
Published: (2022-11-01)

Safety and tolerability of recombinant modified vaccinia virus Ankara expressing an HIV-1 gag/multiepitope immunogen (MVA.HIVA) in HIV-1-infected persons receiving combination antiretroviral therapy.
by: Dorrell, L, et al.
Published: (2007)

Safety and immunogenicity of recombinant low-dosage HIV-1 A vaccine candidates vectored by plasmid pTHr DNA or modified vaccinia virus Ankara (MVA) in humans in East Africa.
by: Jaoko, W, et al.
Published: (2008)

MVA85A: characterising the innate immune responses after vaccination and the effect of TLR1 levels on the acquired antigen-specific immune response
by: Kostov, M, et al.
Published: (2011)

ASSOCIATION OF TLR2, TLR4, TLR9 GENE EXPRESSION RELATED TO INNATE IMMUNITY WITH IN VIVO ACUTE RESPIRATORY INFECTIONS CAUSED BY KLEBSIELLA PNEUMONIAE
by: E. V. Budanova, et al.
Published: (2018-06-01)

Assessment of immunogenicity and efficacy of a Zika vaccine using modified vaccinia Ankara virus as carriers
by: López-Camacho, C, et al.
Published: (2019)

New approaches for improving the immunogenicity of modified vaccinia virus Ankara as a recombinant vaccine vector
by: Alharbi, N
Published: (2014)

Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
by: César López-Camacho, et al.
Published: (2019-11-01)

Protective CD8+ T Cell Response Induced by Modified Vaccinia Virus Ankara Delivering Ebola Virus Nucleoprotein
by: Alexandra Kupke, et al.
Published: (2022-03-01)

Ebola virus – prospects for a novel virus-like-particle-expressing modified vaccinia Ankara-based vaccine
by: Harriet L. Robinson, et al.
Published: (2018-09-01)

A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans.
by: Mwau, M, et al.
Published: (2004)

Retraction: BRCA1 Regulates IFI16 Mediated Nuclear Innate Sensing of Herpes Viral DNA and Subsequent Induction of the Innate Inflammasome and Interferon-β Responses.
by: PLOS Pathogens Editors
Published: (2022-10-01)

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans.
by: McConkey, S, et al.
Published: (2003)

Deletion of fifteen open reading frames from modified vaccinia virus Ankara fails to improve immunogenicity
by: Alharbi, N, et al.
Published: (2015)

Safety and immunogenicity of novel recombinant BCG and modified vaccinia virus Ankara vaccines in neonate rhesus macaques.
by: Rosario, M, et al.
Published: (2010)

Synthetic modified vaccinia Ankara vaccines confer cross-reactive and protective immunity against mpox virus
by: Flavia Chiuppesi, et al.
Published: (2024-02-01)